Abide Therapeutics

NEWS

Abide Therapeutics was acquired by Lundbeck in 2019.

Deals

Lundbeck Acquires Abide Therapeutics for $250M, Gains San Diego Discovery Site

With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.

May 6, 2019

2 min read

Alex Keown

IN THE PRESS

Drug Development

Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, A Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand

May 10, 2016

3 min read

Drug Development

Abide Therapeutics Appoints Richard N. Kender To Board Of Directors

January 19, 2016

3 min read

Business

Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer

January 6, 2016

3 min read

Drug Development

Abide Therapeutics Appoints Donald Hertzog As Vice President, Early Lead Identification

September 8, 2015

3 min read

Drug Development

Abide Therapeutics Announces First Subject Dosed In First-In-Human Clinical Study Of ABX-1431, An Investigational Endocannabinoid System Modulator

July 7, 2015

4 min read

Business

Abide Therapeutics Announces A Collaborative Agreement With The University of Oxford

November 4, 2014

3 min read

Business

Abide Therapeutics Appoints Nancy Thornberry To Board Of Directors

July 29, 2014

3 min read

Business

San Diego Startup Abide Therapeutics Strikes Immune Disorder Pact With Celgene, Financial Details Undisclosed

February 28, 2014

3 min read

AWARDS

JOBS